Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Tourmaline Bio's TOUR-006?
TOUR-006 is a monoclonal antibody commercialized by Tourmaline Bio, with a leading Phase II program in Graves' Ophthalmopathy. According to...
TOUR-006 by Tourmaline Bio for Chronic Kidney Disease (Chronic Renal Failure): Likelihood of Approval
TOUR-006 is under clinical development by Tourmaline Bio and currently in Phase II for Chronic Kidney Disease (Chronic Renal Failure)....
TOUR-006 by Tourmaline Bio for Atherosclerosis: Likelihood of Approval
TOUR-006 is under clinical development by Tourmaline Bio and currently in Phase II for Atherosclerosis. According to GlobalData, Phase II...
TOUR-006 by Tourmaline Bio for Graves' Ophthalmopathy: Likelihood of Approval
TOUR-006 is under clinical development by Tourmaline Bio and currently in Phase II for Graves' Ophthalmopathy. According to GlobalData, Phase...